1. Home
  2. AMWL vs HURA Comparison

AMWL vs HURA Comparison

Compare AMWL & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo American Well Corporation

AMWL

American Well Corporation

HOLD

Current Price

$13.53

Market Cap

179.6M

Sector

Technology

ML Signal

HOLD

Logo TuHURA Biosciences Inc.

HURA

TuHURA Biosciences Inc.

HOLD

Current Price

$2.09

Market Cap

160.5M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
AMWL
HURA
Founded
2006
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Retail: Computer Software & Peripheral Equipment
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
179.6M
160.5M
IPO Year
2020
2010

Fundamental Metrics

Financial Performance
Metric
AMWL
HURA
Price
$13.53
$2.09
Analyst Decision
Hold
Strong Buy
Analyst Count
6
2
Target Price
$7.40
$9.50
AVG Volume (30 Days)
83.7K
174.2K
Earning Date
05-05-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
57.06
47.93
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$4.24
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.71
$0.41
52 Week High
$14.19
$3.43

Technical Indicators

Market Signals
Indicator
AMWL
HURA
Relative Strength Index (RSI) 57.93 48.63
Support Level $4.71 $2.04
Resistance Level $13.82 $2.24
Average True Range (ATR) 0.74 0.10
MACD 0.05 0.00
Stochastic Oscillator 73.19 44.00

Price Performance

Historical Comparison
AMWL
HURA

About AMWL American Well Corporation

American Well Corp is an enterprise platform and software company digitally enabling hybrid care by offering payers and health systems a technology-enabled care platform. The Amwell Platform, its cloud-based enablement platform, digitally enables a scalable healthcare experience across all care settings by enabling critical services like virtual primary care, urgent care, clinical partner programs, scheduling visits, etc. Additionally, the healthcare providers can use the platform to access familiar workflows for taking notes, prescribing, referencing clinical treatment guidelines, and other related activities. The firm also offers various paid services, including licensed clinical staffing, implementation support, workflow design, etc, to help clients execute their hybrid care strategies.

About HURA TuHURA Biosciences Inc.

TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company operates in one reportable segment, which includes all activities related to advancing therapies for cancer treatment.

Share on Social Networks: